Jain Global’s iTeos Therapeutics ITOS Stock Holding History

Jain Global’s Portfolio ITOS Stock Details ITOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-13,800	Closed	-$106K	–	1201
2024 Q4	$106K	Buy	+13,800	New	+$119K	﹤0.01%	689

Other funds holding ITOS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Jain Global's ITOS Position: Q1 2025 in Review

Jain Global sold out of iTeos Therapeutics (ITOS) in Q1 2025, closing a stake of 13,800 shares — an estimated $106K sold.

Jain Global first reported a position in ITOS in Q4 2024 and held it in 1 quarter. The position peaked at $106K in Q4 2024. 131 funds tracked by Wall St. Rank hold ITOS as of Q1 2025.

Jain Global reported no remaining iTeos Therapeutics position as of Q1 2025 after selling out during the quarter.
Jain Global sold 13,800 iTeos Therapeutics shares in Q1 2025, an estimated $106K.
Jain Global first reported a position in iTeos Therapeutics in Q4 2024 and held it in 1 quarter.
Jain Global's iTeos Therapeutics position peaked at $106K in Q4 2024.
131 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q1 2025.

Based on Jain Global's 13F filing for Q1 2025, filed 15 May 2025.